CA3177961A1 - Sirp alpha, sirp beta 1, and sirp gamma antibodies and uses thereof - Google Patents

Sirp alpha, sirp beta 1, and sirp gamma antibodies and uses thereof Download PDF

Info

Publication number
CA3177961A1
CA3177961A1 CA3177961A CA3177961A CA3177961A1 CA 3177961 A1 CA3177961 A1 CA 3177961A1 CA 3177961 A CA3177961 A CA 3177961A CA 3177961 A CA3177961 A CA 3177961A CA 3177961 A1 CA3177961 A1 CA 3177961A1
Authority
CA
Canada
Prior art keywords
seq
antibody
acid sequence
nucleic acid
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3177961A
Other languages
English (en)
French (fr)
Inventor
Sandip PANICKER
Adam David ROSENTHAL
Eileen Lingshu ROSE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Electra Therapeutics Inc
Original Assignee
Electra Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Electra Therapeutics Inc filed Critical Electra Therapeutics Inc
Publication of CA3177961A1 publication Critical patent/CA3177961A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Steroid Compounds (AREA)
CA3177961A 2020-05-08 2021-05-10 Sirp alpha, sirp beta 1, and sirp gamma antibodies and uses thereof Pending CA3177961A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063022309P 2020-05-08 2020-05-08
US63/022,309 2020-05-08
PCT/US2021/031605 WO2021226591A1 (en) 2020-05-08 2021-05-10 Sirp alpha, sirp beta 1, and sirp gamma antibodies and uses thereof

Publications (1)

Publication Number Publication Date
CA3177961A1 true CA3177961A1 (en) 2021-11-11

Family

ID=76197640

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3177961A Pending CA3177961A1 (en) 2020-05-08 2021-05-10 Sirp alpha, sirp beta 1, and sirp gamma antibodies and uses thereof
CA3178038A Pending CA3178038A1 (en) 2020-05-08 2021-05-10 Sirp alpha and sirp beta 1 antibodies and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3178038A Pending CA3178038A1 (en) 2020-05-08 2021-05-10 Sirp alpha and sirp beta 1 antibodies and uses thereof

Country Status (11)

Country Link
US (4) US12503508B2 (https=)
EP (2) EP4146698A1 (https=)
JP (2) JP2023525753A (https=)
KR (2) KR20230017219A (https=)
CN (2) CN115768795A (https=)
AU (2) AU2021267943A1 (https=)
CA (2) CA3177961A1 (https=)
GB (2) GB2613259A (https=)
IL (2) IL298024A (https=)
TW (2) TW202208431A (https=)
WO (2) WO2021226591A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021226591A1 (en) 2020-05-08 2021-11-11 Electra Therapeutics, Inc. Sirp alpha, sirp beta 1, and sirp gamma antibodies and uses thereof
CN118591619A (zh) * 2021-11-24 2024-09-03 雷格细胞股份有限公司 人诱导性调节性t细胞及其制作方法
EP4619435A1 (en) 2022-11-16 2025-09-24 Boehringer Ingelheim International GmbH Predictive efficacy biomarkers for anti-sirpa antibodies
CN117025547B (zh) * 2023-10-08 2023-12-12 迈杰转化医学研究(苏州)有限公司 产生抗b7h3单克隆抗体的杂交瘤细胞株及其应用
TW202529810A (zh) 2023-10-19 2025-08-01 美商電子療法股份有限公司 用於治療噬血球性淋巴組織細胞增生症之ｓｉｒｐ抗體
TW202523701A (zh) 2023-10-19 2025-06-16 美商電子療法股份有限公司 用於治療癌症之ｓｉｒｐ抗體
WO2025226691A1 (en) 2024-04-22 2025-10-30 Electra Therapeutics, Inc. Sirp alpha and beta antibodies for treatment of epstein–barr virus infections
CN119192379B (zh) * 2024-11-22 2025-01-28 四川省医学科学院·四川省人民医院 一种具有高亲和力的抗SIRPγ单克隆抗体及其用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015229448B2 (en) * 2014-03-11 2020-09-03 The Board Of Trustees Of The Leland Stanford Junior University Anti SIRP-alpha antibodies and Bi-specific Macrophage Enhancing antibodies
KR20260030924A (ko) * 2016-08-09 2026-03-06 키맵 리미티드 항-icos 항체
CN118027200A (zh) 2016-12-09 2024-05-14 艾利妥 抗SIRPα抗体及其使用方法
MA47111A (fr) 2016-12-22 2019-10-30 Univ Wake Forest Health Sciences Agents ciblant sirpgamma destinés à être utilisés dans le traitement du cancer
JP7179743B2 (ja) * 2017-02-17 2022-11-29 オーエスイー・イミュノセラピューティクス 抗ＳＩＲＰｇ抗体の新規の使用
CN118267470A (zh) 2017-04-13 2024-07-02 赛罗帕私人有限公司 抗SIRPα抗体
CN118271443A (zh) * 2017-05-16 2024-07-02 拜奥迪斯私人有限公司 抗SIRPα抗体
JP7395471B2 (ja) * 2017-10-13 2023-12-11 オーセ イミュノセラピューティクス 改変抗ＳＩＲＰａ抗体及びその使用
EP3802602A1 (en) * 2018-05-25 2021-04-14 Alector LLC Anti-sirpa antibodies and methods of use thereof
CA3140904A1 (en) 2019-06-24 2020-12-30 Amgen Inc. Inhibition of sirp-gamma for cancer treatment
US20230340112A1 (en) 2020-02-28 2023-10-26 Apexigen, Inc. Anti-sirpa antibodies and methods of use
WO2021226591A1 (en) * 2020-05-08 2021-11-11 Electra Therapeutics, Inc. Sirp alpha, sirp beta 1, and sirp gamma antibodies and uses thereof
WO2023086906A2 (en) 2021-11-10 2023-05-19 Electra Therapeutics, Inc. Sirp gamma antibodies and uses thereof
TW202523701A (zh) 2023-10-19 2025-06-16 美商電子療法股份有限公司 用於治療癌症之ｓｉｒｐ抗體
TW202529810A (zh) 2023-10-19 2025-08-01 美商電子療法股份有限公司 用於治療噬血球性淋巴組織細胞增生症之ｓｉｒｐ抗體

Also Published As

Publication number Publication date
US20250197492A1 (en) 2025-06-19
KR20230017793A (ko) 2023-02-06
GB202218421D0 (en) 2023-01-18
JP2023525753A (ja) 2023-06-19
GB2613464A (en) 2023-06-07
AU2021269130A1 (en) 2022-11-24
JP2023525298A (ja) 2023-06-15
GB2613259A (en) 2023-05-31
EP4146699A1 (en) 2023-03-15
US12503508B2 (en) 2025-12-23
GB202218419D0 (en) 2023-01-18
US12187797B2 (en) 2025-01-07
US20230303685A1 (en) 2023-09-28
US20240239888A1 (en) 2024-07-18
CN115768795A (zh) 2023-03-07
KR20230017219A (ko) 2023-02-03
WO2021226591A1 (en) 2021-11-11
EP4146698A1 (en) 2023-03-15
WO2021226576A1 (en) 2021-11-11
IL297982A (en) 2023-01-01
CA3178038A1 (en) 2021-11-11
TW202208430A (zh) 2022-03-01
IL298024A (en) 2023-01-01
CN115768796A (zh) 2023-03-07
TW202208431A (zh) 2022-03-01
AU2021267943A1 (en) 2022-11-24
US20230174648A1 (en) 2023-06-08

Similar Documents

Publication Publication Date Title
US12187797B2 (en) SIRP α, SIRP β 1, and SIRP γ antibodies and uses thereof
AU2018220150B2 (en) Anti-CD47 Antibodies and Methods of Use Thereof
JP6125489B2 (ja) 抗ｃｄ４０抗体および使用方法
AU2017379382B2 (en) Anti-CD3 Antibody and Molecules Comprising the Antibody
JP2018166522A (ja) 抗ｃｄ４０抗体および使用方法
KR20130028055A (ko) Ｃｄ １２７ 결합 단백질
JP2014515612A5 (https=)
CN114761429B (zh) 新型抗cd3/抗egfr双特异性抗体及其用途
TW202229340A (zh) 多特異性抗體及抗體組合
US20240336686A1 (en) Novel multi-specific molecules
CA3237787A1 (en) Sirp gamma antibodies and uses thereof
WO2025101982A1 (en) Anti-migis-alpha antibodies and methods of use thereof
WO2025209594A1 (zh) 一种抗gucy2c抗体及其多特异性抗体的用途

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250507

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250507

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20250509

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20250509

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250509

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250512

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250728

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250728

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250728

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250728

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250728